Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 491-498 , September 2006

The Effect of Xanthine Oxidase Inhibition Upon Ejection Fraction in Heart Failure Patients: La Plata Study

  • Horacio E. Cingolani, MD, FAHA

      Affiliations

    • From the Centro de Investigaciones Cardiovasculares, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata
    • ,
  • Juan A. Plastino, MD, FACC

      Affiliations

    • Servicio de Cardiología, Hospital Italiano de La Plata
    • ,
  • Eduardo M. Escudero, MD

      Affiliations

    • Servicio de Cardiología, Hospital Italiano de La Plata
    • ,
  • Brian Mangal

      Affiliations

    • Cardiome Pharma Corporation, Vancouver, British Columbia, Canada
    • ,
  • Joanne Brown

      Affiliations

    • From the Centro de Investigaciones Cardiovasculares, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata
    • ,
  • Néstor G. Pérez, PhD

      Affiliations

    • From the Centro de Investigaciones Cardiovasculares, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata
    • Corresponding Author InformationReprint requests: Néstor G. Pérez, PhD, Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Médicas, UNLP, Calle 60 y 120 (1900) La Plata, Argentina.

Received 13 October 2005 ,Revised 12 May 2006 ,Accepted 17 May 2006.

References 

  1. Pérez NG, Gao WD, Marbán E. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998;83:423–430
  2. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999;85:437–445
  3. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407–2411
  4. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002;90:297–304
  5. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000;32:2083–2089
  6. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–226
  7. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619–2624
  8. Anker S, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991–1997
  9. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation. 2004;110:2175–2179
  10. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95:1005–1011
  11. Duncan JG, Ravi R, Stull LB, Murphy AM. Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H1512–H1518
  12. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993;14:1702–1707
  13. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Pérez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2005;11(6 Suppl):S149
  14. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  15. Schiller NB, Shah PM, Crawford M, De Maria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–367
  16. Sahn DJ, De Maria A, Kisslo J, Weymann A. Recommendations regarding quantitation in M-mode echocardiographic measurements. Circulation. 1978;58:1072–1083
  17. Devereux RB, Reichek N. Echocardiographic determinations of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613–618
  18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310
  19. Little RC, Milliken GA, Stroup WW, Wolfinger RD. The SAS system for mixed models, ed 3. Cary (NC): SAS Institute Inc; 1996;p. 87–134
  20. Kogler H, Fraser H, McCune S, Altschuld R, Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003;59:582–592
  21. Dorn GW, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res. 2003;92:1171–1175
  22. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002;34:379–388
  23. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053–1058
  24. Sawyer DB, Colucci WS. Mitochondrial oxidative stress in heart failure: “oxygen wastage” revisited. Circ Res. 2000;86:119–120
  25. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005;11:473–480
  26. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study. 1971–1992: National Health and Nutrition Examination Survey. JAMA. 2000;283:2404–2410
  27. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation. 2001;103:750–755
  28. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris Ap, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006;98:271–279
  29. Demers C, McKelvie RS, Negassa A, Yusuf S. RESOLVD Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J. 2001;142:698–703
  30. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart. 2005;91:749–753
  31. Jourd'heuil D, Mills L, Miles AM, Grisham MB. Effect of nitric oxide on hemoprotein-catalyzed oxidative reactions. Nitric Oxide. 1998;2:37–44
  32. Liu P, Hock CE, Nagele R, Wong PY. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol. 1997;272:H2327–H2336
  33. Yasmin W, Strynadka KD, Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res. 1997;33:422–432
  34. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res. 2000;87:241–247
  35. Gao WD, Atar D, Liu Y, Perez NG, Murphy AM, Marban E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res. 1997;80:393–399
  36. Pérez NG, Hashimoto K, McCune S, Altschuld RA, Marbán E. Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation. 1999;99:1077–1083

 Drs Cingolani and Brown are employees of Cardiome Pharma Corporation, Vancouver, BC, Canada, which sponsored the clinical trial.

PII: S1071-9164(06)00255-7

doi: 10.1016/j.cardfail.2006.05.005

Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 491-498 , September 2006

Article Tools

* Image Usage & Resolution